Unknown

Dataset Information

0

HIV nonnucleoside reverse transcriptase inhibitors and trimethoprim-sulfamethoxazole inhibit plasmodium liver stages.


ABSTRACT:

Background

Although nonnucleoside reverse transcriptase inhibitors (NNRTIs) are usually part of first-line treatment regimens for human immunodeficiency virus (HIV), their activity on Plasmodium liver stages remains unexplored. Additionally, trimethoprim-sulfamethoxazole (TMP-SMX), used for opportunistic infection prophylaxis in HIV-exposed infants and HIV-infected patients, reduces clinical episodes of malaria; however, TMP-SMX effect on Plasmodium liver stages requires further study.

Methods

We characterized NNRTI and TMP-SMX effects on Plasmodium liver stages in vivo using Plasmodium yoelii. On the basis of these results, we conducted in vitro studies assessing TMP-SMX effects on the rodent parasites P. yoelii and Plasmodium berghei and on the human malaria parasite Plasmodium falciparum.

Results

Our data showed NNRTI treatment modestly reduced P. yoelii liver stage parasite burden and minimally extended prepatent period. TMP-SMX administration significantly reduced liver stage parasite burden, preventing development of patent parasitemia in vivo. TMP-SMX inhibited development of rodent and P. falciparum liver stage parasites in vitro.

Conclusions

NNRTIs modestly affect liver stage Plasmodium parasites, whereas TMP-SMX prevents patent parasitemia. Because drugs that inhibit liver stages target parasites when they are present in lower numbers, these results may have implications for eradication efforts. Understanding HIV drug effects on Plasmodium liver stages will aid in optimizing treatment regimens for HIV-exposed and HIV-infected infected patients in malaria-endemic areas.

SUBMITTER: Hobbs CV 

PROVIDER: S-EPMC3488198 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

HIV nonnucleoside reverse transcriptase inhibitors and trimethoprim-sulfamethoxazole inhibit plasmodium liver stages.

Hobbs Charlotte V CV   Voza Tatiana T   De La Vega Patricia P   Vanvliet Jillian J   Conteh Solomon S   Penzak Scott R SR   Fay Michael P MP   Anders Nicole N   Ilmet Tiina T   Li Yonghua Y   Borkowsky William W   Krzych Urszula U   Duffy Patrick E PE   Sinnis Photini P  

The Journal of infectious diseases 20121201 11


<h4>Background</h4>Although nonnucleoside reverse transcriptase inhibitors (NNRTIs) are usually part of first-line treatment regimens for human immunodeficiency virus (HIV), their activity on Plasmodium liver stages remains unexplored. Additionally, trimethoprim-sulfamethoxazole (TMP-SMX), used for opportunistic infection prophylaxis in HIV-exposed infants and HIV-infected patients, reduces clinical episodes of malaria; however, TMP-SMX effect on Plasmodium liver stages requires further study.<h  ...[more]

Similar Datasets

| S-EPMC1635531 | biostudies-literature
| S-EPMC2809083 | biostudies-literature
| S-EPMC7125863 | biostudies-literature
| S-EPMC6631718 | biostudies-literature
| S-EPMC1346823 | biostudies-literature
| S-EPMC1298242 | biostudies-literature
| S-EPMC4147682 | biostudies-literature
| S-EPMC6467559 | biostudies-literature
2018-12-12 | E-MTAB-7087 | biostudies-arrayexpress
| S-EPMC6629025 | biostudies-literature